FDA Refuses to Approve Akeso-Summit Lung Cancer Drug After Survival Miss
The FDA has turned down ivonescimab, a China-developed lung cancer drug, saying Summit Therapeutics' application can't be approved as filed. The international HARMONi trial showed the drug plus chemo delayed cancer progression, but the survival gain didn't clear the agency's statistical bar. It's a hard stop for a treatment once billed as a Keytruda killer.
- Original source: theepochtimes.com.
- The source published it on Nov 16, 2026 at 10:14 PM.
- No second outlet has reported it yet. Treat it as a single-source claim.
Summit Therapeutics said on Nov. 15 that the FDA issued a response letter stating its application for ivonescimab could not be approved in its current form. The filing sought clearance to pair the drug with chemotherapy for patients with a specific advanced lung cancer whose disease had worsened despite earlier targeted treatment. The FDA's stated reason: the evidence didn't establish a statistically significant improvement in overall survival.
The verdict rested on HARMONi, an international Phase III trial of 438 patients whose advanced lung cancer carried mutations in a gene called EGFR. Patients on ivonescimab plus pemetrexed and carboplatin went a median of 6.8 months before their cancer worsened or they died, versus 4.4 months for those on chemotherapy and a placebo. Median survival came in at 16.8 months against 14 months — better, but short of what the trial's statistics demanded.
The agency had telegraphed the requirement. In a Nov. 4 disclosure, Summit acknowledged the FDA wanted a statistically significant overall survival gain for this treatment setting. Summit later reported stronger survival results from longer patient follow-up, but those analyses came after the trial's primary assessment and didn't move the agency.
Ivonescimab is designed to block two proteins tied to cancer growth: one that helps tumors dodge the immune system, another that feeds them blood vessels. China's drug regulator cleared it in May 2024 for certain advanced lung cancer patients, then added approvals in April 2025 and August 2026. Akeso licensed U.S., Canadian, European and Japanese rights to Summit in December 2022 for $500 million upfront, with a deal that could reach $5 billion. On Oct. 5, AstraZeneca completed a $2 billion investment in Summit to fund further ivonescimab work.
The rejection covers the international HARMONi trial, not the China-only HARMONi-2 study that made ivonescimab famous. There, patients survived a median of 30.8 months versus 22.6 months on Merck's Keytruda, according to September results — though that trial tested first-line treatment in a different group of lung cancers and compared the drug directly to Keytruda rather than adding it to chemotherapy. U.S. lawmakers have separately pressed the FDA on Chinese trial data: Reps. John Moolenaar (R-Mich.) and Ben Cline (R-Va.) wrote on Aug. 21 urging the agency to reject such data unless it had inspected the site within 12 months, citing three patient deaths in Chinese gene-editing studies. In May 2025, the FDA reported falsified or invalid research data at two Chinese labs. The stated reason for the ivonescimab decision, however, was survival evidence, not data reliability.
Summit isn't done with the U.S. market. It's leaning on HARMONi-3, which pits ivonescimab plus chemotherapy against a Keytruda-based regimen in first-line advanced lung cancer patients. Per its latest quarterly disclosure, Summit expects the first major results from one patient group in the fourth quarter of 2026, with an additional survival analysis in the first half of 2027. The FDA, meanwhile, keeps greenlighting Chinese-developed drugs — on Nov. 10 it approved Abbisko Therapeutics' pimicotinib for a rare tumor condition affecting joints and surrounding tissue. The Epoch Times said it contacted the FDA and Summit for the original response letter and didn't hear back by publication.
TopicsFDA · Summit Therapeutics · Akeso · ivonescimab · AstraZeneca · Merck · Keytruda · Abbisko Therapeutics
Source: theepochtimes.com
Written by AI from verified reporting.
More stories
- Health & science targetedonc.com 0 viewsFDA clears Biocon's Perjeta biosimilar, but US shelves wait until 2028
- Health & science healthandme.com 0 viewsEurope approves Revolution Medicines' RAS-blocking pancreatic cancer pill
- Health & science wdsu.com 0 viewsFDA Greenlights First Treatment for Deadly Sanfilippo Syndrome
- Health & science finance.yahoo.com 0 viewsNovartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR

